Cosciens Biopharma Stock Performance
| CSCI Stock | 2.03 0.03 1.46% |
On a scale of 0 to 100, COSCIENS Biopharma holds a performance score of 4. The firm shows a Beta (market volatility) of 0.47, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, COSCIENS Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding COSCIENS Biopharma is expected to be smaller as well. Please check COSCIENS Biopharma's semi variance, and the relationship between the maximum drawdown and rate of daily change , to make a quick decision on whether COSCIENS Biopharma's price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in COSCIENS Biopharma are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak fundamental indicators, COSCIENS Biopharma demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.46) | Five Day Return (1.46) | Year To Date Return (1.46) | Ten Year Return (66.17) | All Time Return (66.17) |
Last Split Factor 1:4 | Last Split Date 2024-05-03 |
1 | Long Term Trading Analysis for - news.stocktradersdaily.com | 12/04/2025 |
2 | Why COSCIENS Biopharma Inc. stock could be next big winner - Trade Exit Summary Smart Investment Allocation Insights - DonanmHaber | 12/19/2025 |
3 | Meet CSCI The First Family of Florida Shell Construction | 01/08/2026 |
4 | Value Recap What is COSCIENS Biopharma Incs revenue forecast - Weekly Investment Report Entry Point Confirmation Alerts - baoquankhu1.vn | 01/12/2026 |
5 | Stock Trading Blueprint - Stock Traders Daily | 01/28/2026 |
6 | Daily Stock Insights - Stock Traders Daily | 02/09/2026 |
7 | On The My Stocks Page - Stock Traders Daily | 02/17/2026 |
| Begin Period Cash Flow | 6.7 M | |
| Total Cashflows From Investing Activities | 25.1 M |
COSCIENS Biopharma Relative Risk vs. Return Landscape
If you would invest 209.00 in COSCIENS Biopharma on November 21, 2025 and sell it today you would lose (6.00) from holding COSCIENS Biopharma or give up 2.87% of portfolio value over 90 days. COSCIENS Biopharma is currently generating 0.8611% in daily expected returns and assumes 14.0773% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than COSCIENS, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
COSCIENS Biopharma Target Price Odds to finish over Current Price
The tendency of COSCIENS Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.03 | 90 days | 2.03 | about 71.61 |
Based on a normal probability distribution, the odds of COSCIENS Biopharma to move above the current price in 90 days from now is about 71.61 (This COSCIENS Biopharma probability density function shows the probability of COSCIENS Stock to fall within a particular range of prices over 90 days) .
COSCIENS Biopharma Price Density |
| Price |
Predictive Modules for COSCIENS Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as COSCIENS Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of COSCIENS Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
COSCIENS Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. COSCIENS Biopharma is not an exception. The market had few large corrections towards the COSCIENS Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold COSCIENS Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of COSCIENS Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.21 | |
β | Beta against Dow Jones | 0.47 | |
σ | Overall volatility | 0.35 | |
Ir | Information ratio | 0.01 |
COSCIENS Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of COSCIENS Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for COSCIENS Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| COSCIENS Biopharma is way too risky over 90 days horizon | |
| COSCIENS Biopharma appears to be risky and price may revert if volatility continues | |
| COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.78 M. Net Loss for the year was (15.31 M) with profit before overhead, payroll, taxes, and interest of 4.42 M. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| COSCIENS Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: On The My Stocks Page - Stock Traders Daily |
COSCIENS Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of COSCIENS Stock often depends not only on the future outlook of the current and potential COSCIENS Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. COSCIENS Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.6 M | |
| Cash And Short Term Investments | 16.4 M |
COSCIENS Biopharma Fundamentals Growth
COSCIENS Stock prices reflect investors' perceptions of the future prospects and financial health of COSCIENS Biopharma, and COSCIENS Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on COSCIENS Stock performance.
| Return On Equity | -1.13 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (2.00) % | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.31 M | ||||
| Shares Outstanding | 3.18 M | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 0.92 X | ||||
| Revenue | 13.78 M | ||||
| Gross Profit | 4.42 M | ||||
| EBITDA | (13.49 M) | ||||
| Net Income | (15.31 M) | ||||
| Total Debt | 2.31 M | ||||
| Book Value Per Share | 2.23 X | ||||
| Cash Flow From Operations | (14.57 M) | ||||
| Earnings Per Share | (6.54) X | ||||
| Market Capitalization | 8.64 M | ||||
| Total Asset | 35.07 M | ||||
| Retained Earnings | (12.11 M) | ||||
| Working Capital | 16.76 M | ||||
About COSCIENS Biopharma Performance
By evaluating COSCIENS Biopharma's fundamental ratios, stakeholders can gain valuable insights into COSCIENS Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if COSCIENS Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if COSCIENS Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 161.73 | 123.23 | |
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.85) | (0.89) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (1.34) | (1.40) |
Things to note about COSCIENS Biopharma performance evaluation
Checking the ongoing alerts about COSCIENS Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for COSCIENS Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| COSCIENS Biopharma is way too risky over 90 days horizon | |
| COSCIENS Biopharma appears to be risky and price may revert if volatility continues | |
| COSCIENS Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.78 M. Net Loss for the year was (15.31 M) with profit before overhead, payroll, taxes, and interest of 4.42 M. | |
| COSCIENS Biopharma generates negative cash flow from operations | |
| COSCIENS Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: On The My Stocks Page - Stock Traders Daily |
- Analyzing COSCIENS Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether COSCIENS Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining COSCIENS Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating COSCIENS Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of COSCIENS Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of COSCIENS Biopharma's stock. These opinions can provide insight into COSCIENS Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for COSCIENS Stock analysis
When running COSCIENS Biopharma's price analysis, check to measure COSCIENS Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy COSCIENS Biopharma is operating at the current time. Most of COSCIENS Biopharma's value examination focuses on studying past and present price action to predict the probability of COSCIENS Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move COSCIENS Biopharma's price. Additionally, you may evaluate how the addition of COSCIENS Biopharma to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |